{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:19:39Z","timestamp":1789172379153,"version":"build-2803163510"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1097\/md.0000000000008300","type":"journal-article","created":{"date-parts":[[2017,10,18]],"date-time":"2017-10-18T16:39:49Z","timestamp":1508344789000},"page":"e8300","source":"Crossref","is-referenced-by-count":34,"title":["Dose, duration and strain of bacillus Calmette\u2013Guerin in the treatment of nonmuscle invasive bladder cancer"],"prefix":"10.1097","volume":"96","author":[{"given":"Yongjun","family":"Quan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Wook","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Hoe","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Suk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Hyeon","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-69-20210226","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU Guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"R2-69-20210226","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3233\/BLC-150034","article-title":"Comparison of guidelines on non-muscle invasive bladder cancer (EAU, CUA, AUA, NCCN, NICE)","volume":"2","author":"Power","year":"2016","journal-title":"Bladder Cancer"},{"key":"R3-69-20210226","doi-asserted-by":"crossref","first-page":"14","DOI":"10.5173\/ceju.2013.01.art5","article-title":"EORTC risk tables \u2013 their usefulness in the assessment of recurrence and progression risk in non-muscle-invasive bladder cancer in Polish patients","volume":"66","author":"Borkowska","year":"2013","journal-title":"Cent European J Urol"},{"key":"R4-69-20210226","first-page":"418","article-title":"The value of EORTC risk tables in evaluating recurrent non-muscle-invasive bladder cancer in everyday practice","volume":"66","author":"Walczak","year":"2014","journal-title":"Cent European J Urol"},{"key":"R5-69-20210226","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4103\/0970-1591.38608","article-title":"Bacillus Calmette-Guerin in the management of superficial bladder cancer","volume":"24","author":"Kapoor","year":"2008","journal-title":"Indian J Urol"},{"key":"R6-69-20210226","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"R7-69-20210226","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Gu\u00e9rin reduce recurrence in patients with superficial bladder cancer? a meta-analysis of randomized trials","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"R8-69-20210226","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Gu\u00e9rin in patients with high-risk bladder cancer","volume":"99","author":"G\u00e5rdmark","year":"2007","journal-title":"BJU Int"},{"key":"R9-69-20210226","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-(2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. a prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"R10-69-20210226","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Gu\u00e9rin, and bacillus Calmette-Gu\u00e9rin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"R11-69-20210226","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.eururo.2012.08.061","article-title":"ICUD-EAU international consultation on bladder cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"R12-69-20210226","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-5347(17)37532-8","article-title":"Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer","volume":"147","author":"Morales","year":"1992","journal-title":"J Urol"},{"key":"R13-69-20210226","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF02550276","article-title":"Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer","volume":"30","author":"Yal\u00e7inkaya","year":"1998","journal-title":"Int Urol Nephrol"},{"key":"R14-69-20210226","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81\u200amg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27\u200amg in superficial bladder cancer","volume":"89","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"R15-69-20210226","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1046\/j.0919-8172.2003.00607.x","article-title":"Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Gu\u00e9rin for superficial bladder cancer recurrence","volume":"10","author":"Irie","year":"2003","journal-title":"Int J Urol"},{"key":"R16-69-20210226","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"R17-69-20210226","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0970-1591.29117","article-title":"A randomized trial comparing low dose (40 or 80\u200amg) with standard dose (120\u200amg) of bacillus Calmette-Guerin for superficial bladder cancer","volume":"22","author":"Vijjan","year":"2006","journal-title":"Indian J Urol"},{"key":"R18-69-20210226","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","article-title":"The safety and efficacy of different doses of bacillus Calmette Gu\u00e9rin in superficial bladder transitional cell carcinoma","volume":"70","author":"Agrawal","year":"2007","journal-title":"Urology"},{"key":"R19-69-20210226","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"R20-69-20210226","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.1987.5.3.441","article-title":"A prospective randomized trial of maintenance versus non-maintenance intravesical bacillus Calmette-Gu\u00e9rin therapy of superficial bladder cancer","volume":"5","author":"Badalament","year":"1987","journal-title":"J Clin Oncol"},{"key":"R21-69-20210226","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0022-5347(01)65183-8","article-title":"A 12 versus 6-week course of bacillus Calmette-Guerin prophylaxis for the treatment of high risk superficial bladder cancer","volume":"157","author":"Gruenwald","year":"1997","journal-title":"J Urol"},{"key":"R22-69-20210226","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin immunotherapy for recurrence Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"R23-69-20210226","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/S0022-5347(05)66333-1","article-title":"Control group and maintenance treatment with bacillus Calmette-Gu\u00e9rin for carcinoma in situ and\/or high grade bladder tumors","volume":"165","author":"Palou","year":"2001","journal-title":"J Urol"},{"key":"R24-69-20210226","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus Calmette-Gu\u00e9rin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group","volume":"17","author":"Koga","year":"2010","journal-title":"Int J Urol"},{"key":"R25-69-20210226","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1464-410X.2010.09891.x","article-title":"Maintenance therapy with bacillus Calmette-Gu\u00e9rin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer","volume":"108","author":"Hinotsu","year":"2011","journal-title":"BJU Int"},{"key":"R26-69-20210226","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly bacillus Calmette-Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non\u2013muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO Study 98013","volume":"68","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2015","journal-title":"Eur Urol"},{"key":"R27-69-20210226","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/iju.13167","article-title":"Insignificant role of bacillus Calmette\u2013Gu\u00e9rin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: results from a randomized trial","volume":"23","author":"Nakai","year":"2016","journal-title":"Int J Urol"},{"key":"R28-69-20210226","first-page":"10","article-title":"Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group","volume":"14","author":"Witjes","year":"1996","journal-title":"Semin Urol Oncol"},{"key":"R29-69-20210226","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Gu\u00e9rin therapy with the Tokyo or Connaught strain for non-muscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol"},{"key":"R30-69-20210226","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol"},{"key":"R31-69-20210226","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"R32-69-20210226","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1200\/JCO.2004.01.0454","article-title":"Reporting recommendations for tumor marker prognostic studies","volume":"23","author":"McShane","year":"2005","journal-title":"J Clin Oncol"},{"key":"R33-69-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R34-69-20210226","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"R35-69-20210226","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"R36-69-20210226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R37-69-20210226","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"R38-69-20210226","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4111\/kju.2014.55.10.643","article-title":"Predicting recurrence and progression of non-muscle-invasive bladder cancer in Korean patients: a comparison of the EORTC and CUETO models","volume":"55","author":"Choi","year":"2014","journal-title":"Korean J Urol"},{"key":"R39-69-20210226","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4111\/kju.2010.51.3.165","article-title":"The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus Calmette-Guerin instillation","volume":"51","author":"Seo","year":"2010","journal-title":"Korean J Urol"},{"key":"R40-69-20210226","doi-asserted-by":"crossref","first-page":"e2176","DOI":"10.1097\/MD.0000000000002176","article-title":"Low-dose versus standard dose of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"94","author":"Zeng","year":"2015","journal-title":"Medicine"},{"key":"R41-69-20210226","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.clgc.2013.07.007","article-title":"Significance of positive urine cytology on progression and cancer-specific mortality of non\u2013muscle-invasive bladder cancer","volume":"12","author":"Koga","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"R42-69-20210226","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with non-muscle invasive bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J Urol"},{"key":"R43-69-20210226","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00345-013-1205-1","article-title":"Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC)","volume":"32","author":"Shindo","year":"2014","journal-title":"World J Urol"},{"key":"R44-69-20210226","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1007\/s13277-013-1547-8","article-title":"Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG","volume":"35","author":"Zachos","year":"2014","journal-title":"Tumor Biol"},{"key":"R45-69-20210226","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3349\/ymj.2016.57.4.855","article-title":"Prognostic factors for recurrence and progression in Korean non-muscle-invasive bladder cancer patients: a retrospective, multi-institutional study","volume":"57","author":"Kim","year":"2016","journal-title":"Yonsei Med J"},{"key":"R46-69-20210226","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(97)02419-7","article-title":"Language bias in randomised controlled trials published in English and German","volume":"350","author":"Egger","year":"1997","journal-title":"Lancet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:36:45Z","timestamp":1620959805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201710200-00069"}},"subtitle":["Meta-analysis of randomized clinical trials"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":46,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008300","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}